What oral medications are appropriate for treating infections caused by extended-spectrum beta-lactamase (ESBL)-producing organisms?

Oral Treatment for ESBL Infections

For ESBL urinary tract infections, fosfomycin is the preferred oral agent with 97% susceptibility, followed by nitrofurantoin (94% susceptibility) for uncomplicated cases, while oral fluoroquinolones or trimethoprim-sulfamethoxazole can be used for step-down therapy in complicated UTIs if susceptibility is confirmed 1, 2.

Urinary Tract Infections (Most Common ESBL Indication)

Uncomplicated UTI

The evidence strongly supports specific oral agents based on susceptibility patterns:

• Fosfomycin 3g PO single dose or every other day - highest susceptibility at 97% and lowest resistance rate (4.9%) 1, 3, 2
• Nitrofurantoin 100mg PO four times daily - 94% susceptibility 1, 2
• Pivmecillinam - 85% susceptibility where available 1

Duration: 3-7 days 2

Complicated UTI/Pyelonephritis

For step-down or outpatient oral therapy after initial IV treatment:

• Fluoroquinolones (if susceptible) - good oral bioavailability makes them appropriate for stable patients transitioning from IV therapy, though direct evidence is limited 4
• Oral fosfomycin - very low certainty evidence when compared to ertapenem, but can be considered 4
• Trimethoprim-sulfamethoxazole (if susceptible) - reasonable option for step-down therapy 5

Duration: 5-7 days total 2

Critical Caveat: Avoid Amoxicillin-Clavulanate

Despite in vitro susceptibility, amoxicillin-clavulanate should be avoided for ESBL infections 3. The most recent 2026 study demonstrated worst outcomes with oral amoxicillin-clavulanate even when isolates tested susceptible 3. Earlier studies showed:

• Treatment failure rates of 10.8-15.3% 6
• Resistance development during therapy, especially with high MICs (≥8 mg/mL) 6
• Significantly higher failure rates with Klebsiella species (33.3%) versus E. coli (6.5%) 6

The exception is wound/skin infections where amoxicillin-clavulanate showed no resistance in ESBL producers 7, though this represents a different clinical context.

Experimental Combination Therapy

One small study suggests cefixime plus amoxicillin-clavulanate combination showed 90% clinical/microbiological resolution in 20 ESBL UTI patients with positive in vitro synergy testing 8. However, this requires specialized synergy testing and lacks guideline support—consider only when other options are unavailable.

Non-UTI Infections

For non-urinary ESBL infections, oral options are extremely limited. The guidelines 4, 2 do not recommend oral therapy for:

• Bloodstream infections
• Pneumonia
• Complicated intra-abdominal infections

These require IV carbapenem-sparing agents (ceftazidime-avibactam, aminoglycosides, tigecycline) or carbapenems.

Key Predictors Requiring ESBL Coverage

Consider empiric ESBL coverage if patient has 3:

• Recent hospitalization (within 3 months)
• Known MDRO carriage (within 2 years)
• Recent antimicrobial exposure (within 3 months)
• Prior UTI (within 6 months)

Practical Algorithm

1. Confirm ESBL and obtain susceptibilities - essential for oral therapy selection
2. For uncomplicated UTI: Start fosfomycin or nitrofurantoin empirically
3. For complicated UTI: Begin IV therapy, transition to oral fluoroquinolone or TMP-SMX only if susceptible
4. Avoid amoxicillin-clavulanate regardless of reported susceptibility
5. Duration: 3-7 days for uncomplicated, 5-7 days for complicated UTI